Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 801–900 of 1,000
MN1 and PTEN gene expression in acute myeloid leukemia
Zayed, R. A., El-Taweel, M., Botros, S. K. A., & Zaki, M. A. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160235 · Cited by 15
Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia
Pulikkan, J. A., & Castilla, L. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00129 · Cited by 18
“In spite of the morphology, the inv(16) AML transcriptome clusters as a single entity, suggesting a common underlying molecular alteration (12).”
BackgroundLi, L., & Cai, M. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2914103 · Cited by 15
Joshi, A., Beck, Y., & Michoel, T. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2014.0290 · Cited by 15
“1) we have used gene expression data (both microarray and RNA-seq) from five different studies (9-13) comprising a total of 771 AML samples.”
MethodVorbach, S. M., Gründer, A., Zhou, F., Koellerer, C., Jutzi, J. S., Simoni, M., Riccetti, L., Valk, P. J. M., Sanders, M. A., Müller‐Tidow, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0577-7 · Cited by 15
Self-citationAbbas, H. A., Mohanty, V., Wang, R., Huang, Y., Liang, S., Wang, F., Zhang, J., Qiu, Y., Hu, C. W., Qutub, A. A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.705627 · Cited by 15
Hackl, H., Stocker, G., Charoentong, P., Mlecnik, B., Bindea, G., Galon, J., & Trajanoski, Z. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.08.012 · Cited by 17
Singh, S. A., Koschmieder, S., Gelsing, S., Stocking, C., Stehling, M., Thiede, C., Thoennissen, N. H., Köhler, G., Valk, P. J. M., Delwel, R., et al. (2010) · Blood · doi:10.1182/blood-2009-03-210070 · Cited by 15
Self-citationLiu, H., Shih, L., Chen, M.-J. M., Wang, C.-C., Yeh, T., Lin, T., Chen, C., Lin, C., & Liang, D. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.02.003 · Cited by 15
“Major subtypes of AML were well classified and predicted by gene expression profiling (10,25,27).”
BackgroundL-asparaginase induces in AML U937 cells apoptosis via an AIF-mediated mechanism
He, Y. (2014) · Frontiers in bioscience · doi:10.2741/4222 · Cited by 15
“AML gene expression raw data (GSE1729, GSE10358 GSE6891, and GSE1159) (14-17) were obtained from the”
MethodInfluentialAbe, M., Pelus, L. M., Singh, P., Hirade, T., Onishi, C., Purevsuren, J., Taketani, T., Yamaguchi, S., & Fukuda, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158290 · Cited by 15
Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1
Fraszczak, J., Helness, A., Chen, R., Vadnais, C., Robert, F., Khandanpour, C., & Möröy, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160344 · Cited by 15
“Expression profiling was carried out using Affymetrix arrays according to published procedures [38].”
MUC 1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism
Stroopinsky, D., Rajabi, H. N., Nahas, M. R., Rosenblatt, J. M., Rahimian, M., Pyzer, A. R., Tagde, A., Kharbanda, A., Jain, S. S., Kufe, T., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13662 · Cited by 15
Stoner, S. A., Liu, K. T. H., Andrews, E. T., Liu, M., Arimoto, K., Yan, M., Davis, A. G., Weng, S., Dow, M. T., Su, X., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0282-9 · Cited by 17
Toward a functional taxonomy of cancer
Golub, T. R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.007 · Cited by 15
Pharmacogenomics in Acute Myeloid Leukemia
Roumier, C., & Cheok, M. H.-C. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.130 · Cited by 15
Statistical Applications in Genetics and Molecular Biology
(2013) · Statistical Applications in Genetics and Molecular Biology · doi:10.1515/sagmb · Cited by 15
Rewiring of the Transcription Factor Network in Acute Myeloid Leukemia
Assi, S. A., Bonifer, C., & Cockerill, P. N. (2019) · Cancer Informatics · doi:10.1177/1176935119859863 · Cited by 16
Su, X., Zhao, Q., Ke, J.-M., Wu, D., Zhu, X. J., Lin, J., & Deng, Z.-Q. (2020) · Cancer Management and Research · doi:10.2147/cmar.s278499 · Cited by 14
circRNAs as prognostic markers in pediatric acute myeloid leukemia
Sun, H., Xie, Y., Wu, X., Hu, W., Chen, X., Wu, K., Wang, H., Zhao, S., Shi, Q., Wang, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216880 · Cited by 16
EXPECTATION-MAXIMIZATION METHOD FOR RECONSTRUCTING TUMOR PHYLOGENIES FROM SINGLE-CELL DATA
Pennington, G., Smith, C. A., Shackney, S. E., & Schwartz, R. S. (2006) · IEEE Computational Systems Bioinformatics Conference (CSB) · doi:10.1142/9781860947575_0044 · Cited by 14
Li, G., ZHANG, L., LIU, J., XIAO, T., Liu, G., WANG, J., & Hou, M. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5064 · Cited by 14
“It has been reported that RPS15A gene expression was upregulated in leukemia tissues at the mRNA level (34-36).”
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome
Visani, G., Loscocco, F., Isidori, A., & Piccaluga, P. P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1475225 · Cited by 14
Applications of Microarray Technology to Acute Myelogenous Leukemia
Goswami, R. S., Sukhai, M. A., Thomas, M., Reis, P. P., & Kamel‐Reid, S. (2008) · Cancer Informatics · doi:10.4137/cin.s1015 · Cited by 14
“For example, in the study conducted by Valk et al. (2004), they identified 16 groups of AMLs with distinct molecular signatures, associated with known and previouslyunidentifi ed disease subtypes.”
BackgroundInfluentialChemical strategies for immobilization of oligonucleotides
Sethi, D., Gandhi, R., Kuma, P., & Gupta, K. C. (2009) · Biotechnology Journal · doi:10.1002/biot.200900162 · Cited by 14
Capala, M. E., Vellenga, E., & Schuringa, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111568 · Cited by 11
“Finally, we analyzed the expression of ELMO1 in a third independent cohort of NK AML patients [6,29], which again indicated that ELMO1 significantly predicts poor survival (p = 0.”
BackgroundMethodInfluentialSplicing factor mutations in AML
Ogawa, S. (2014) · Blood · doi:10.1182/blood-2014-04-566752 · Cited by 16
Mapping of MN1 Sequences Necessary for Myeloid Transformation
Kandilci, A., Surtel, J., Janke, L. J., Neale, G. A. M., Terranova, S., & Grosveld, G. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061706 · Cited by 14
Wertheim, G. B. W., Hexner, E. O., & Bagg, A. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0009-0 · Cited by 18
“Interestingly, many of the transcriptome-based subgroups correlate with specific mutations, but discrete subgroups that are defined solely by their transcription profile are also identified [108].”
BackgroundWeng, S., Matsuura, S., Mowery, C. T., Stoner, S. A., Lam, K., Ran, D., Davis, A. G., Lo, M.-C., & Zhang, D.-E. (2016) · Leukemia · doi:10.1038/leu.2016.167 · Cited by 14
Dzneladze, I., Woolley, J. F., Rossell, C., Han, Y., Rashid, A., Jain, M. D., Reimand, J., Minden, M. D., & Salmena, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191510 · Cited by 14
Wu, S. K., Fahmy, N., & Alachkar, H. (2019) · Metabolism Open · doi:10.1016/j.metop.2019.100009 · Cited by 18
“To analyze differential expression for the MTM genes in normal tissue vs AML we utilized the Andersson Leukemia dataset (GSE7186) [17] with 6 samples from healthy bone marrow and 23 samples from patients with AML, the Haferlach Leukemia dataset (GSE13159) [18] with 74 samples from healthy donor peripheral blood mononu…”
MethodMineralocorticoid receptor antagonists, heart failure and predictive biomarkers
Karthigan, N., Lockwood, S., White, A., Yang, J., & Young, M. J. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0323 · Cited by 16
“As early as the 2000s, microarray technology was used to identify novel prognostic markers of acute myeloid leukaemia (Valk et al. 2004).”
A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia
Yin, B., Tsai, M., Hasz, D. E., Rathe, S. K., Beau, M. M. L., & Largaespada, D. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404595 · Cited by 14
RetractedBloomfield, C. D., Mrózek, K., & Caligiuri, M. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-9002 · Cited by 14
Abramowitz, J., Neuman, T., Perlman, R., & Ben‐Yehuda, D. (2017) · BMC Medical Genomics · doi:10.1186/s12920-017-0249-2 · Cited by 14
O’Connell, G. C., Wang, J., & Smothers, C. G. (2023) · Genomics · doi:10.1016/j.ygeno.2023.110708 · Cited by 20
“…have performed either primary analyses or secondary meta-analyses of gene expression data generated from whole blood in attempts to better understand the immune pathophysiology associated with a broad range of human disease states, or to identify biomarkers with potential diagnostic utility [2–8].”
BackgroundGene expression analysis reveals HOX gene upregulation in trisomy 8 AML
Kok, C. H., Brown, A. L., Ekert, P. G., & D’Andrea, R. J. (2010) · Leukemia · doi:10.1038/leu.2010.85 · Cited by 13
Acute Myeloid Leukemia with Normal Cytogenetics
Mawad, R., & Estey, E. H. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0252-x · Cited by 16
“Initial published results confirmed the ability of unsupervised genetic cluster analysis to generate specific molecular signatures that were associated with AML [71].”
Tholouli, E., MacDermott, S. A., Hoyland, J. A., Yin, J. L., & Byers, R. J. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.092 · Cited by 14
Prognostic Significance of Leukopenia at the Time of Diagnosis in Acute Myeloid Leukemia
Arellano, M. L., Bernal‐Mizrachi, L., Pan, L., Tighiouart, M., Souza, L. R., Guo, X., McLemore, M. L., Lima, L. M., Sunay, S., Heffner, L. T., et al. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.035 · Cited by 13
Nikfarjam, S., Tohidkia, M. R., Mehdipour, T., Soleimani, R., Rahimi, A. A. R., & Nouri, M. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.072 · Cited by 13
“(%) CDR1 (27-34) CDR2 (56-63) CDR3 (105-113) CDR1 (27-32) CDR2 (56-58) CDR3(105-113)”
Huang, S., Huang, Z., Ma, C., Luo, L., Li, Y., Wu, Y., Ren, Y., & Feng, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.54 · Cited by 13
“Gene expression was obtained from published microarray data using Affymetrix Human Genome 133 plus 2.0 as well as U133A Gene Chips (accession number: GSE9476, GSE1159, GSE6891, GSE12417) (24,25,27,28).”
BackgroundInfluentialCharacterization of functional transposable element enhancers in acute myeloid leukemia
Zeng, Y., Cao, Y., Halevy, R. S., Nguyen, P., Liu, D., Zhang, X., Ahituv, N., & Han, J. J. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1574-x · Cited by 13
Johansson, B., & Harrison, C. J. (2010) · Wiley eBooks · doi:10.1002/9781118010136.ch5 · Cited by 16
Noordermeer, S. M., Monteferrario, D., Sanders, M. A., Bullinger, L., Jansen, J. H., & van der Reijden, B. A. (2012) · Blood · doi:10.1182/blood-2012-02-405019 · Cited by 13
Chung, C. H., Wong, S. J., Ang, K. K., Hammond, E. H., Dicker, A. P., Harari, P. M., & Le, Q. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.090 · Cited by 14
Burnett, A. K., & Venditti, A. (2010) · Wiley eBooks · doi:10.1002/9781444323160.ch23 · Cited by 14
Cbfβ Reduces Cbfβ-SMMHC–Associated Acute Myeloid Leukemia in Mice
Heilman, S. A., Kuo, Y., Goudswaard, C. S., Valk, P. J. M., & Castilla, L. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0959 · Cited by 14
Self-citationOver-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia
Liu, L., Zhang, D., Mao, X., Zhang, X.-H., & Zhang, B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.094 · Cited by 13
M@CBETH: a microarray classification benchmarking tool
Pochet, N. L. M. M., Janssens, F., Smet, F. D., Marchal, K., Suykens, J. A. K., & Moor, B. L. R. D. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti495 · Cited by 13
“…technology has shown to be useful in supporting clinical management decisions for individual patients [e.g. breast cancer (van't Veer et al., 2002), acute myeloid leukemia (Valk et al., 2004) and ovarian cancer (De Smet et al., 2005)] in combination with classification methods (Furey et al., 2000).”
Liu, Y., Liu, W., Lai, A., Mei, Y., Wang, Y., Wei, H., Rao, Q., Gu, R., Mi, Y., Wang, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01144-1 · Cited by 12
“We identi fi ed similar three clusters from 46 t(8;21) AML patients of the HOVON cohort [11], suggesting the accuracy of our clustering strategy (Supplemental Fig.”
BackgroundLoss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3 -ITD acute myeloid leukemia
Kresinsky, A., Bauer, R., Schnoeder, T. M., Berg, T., Meyer, D., Ast, V., König, R., Serve, H. L., Heidel, F. H., Böhmer, F., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185306 · Cited by 12
Bourkoula, K., Englert, C., Giaisi, M., Köhler, R., Krammer, P. H., & Li‐Weber, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28379 · Cited by 12
Wertheim, G. B. W., & Bagg, A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.19 · Cited by 15
Chromatin Structure Profiling Identifies Crucial Regulators of Tumor Maintenance
Bonifer, C., & Cockerill, P. N. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.003 · Cited by 12
“In the case of acute myeloid leukemia (AML), the comparison of normal and malignant cells demonstrated that (i) the genotype and the expression phenotype of malignant cells are highly correlated, and (ii) that each AML subtype defined by mutation status expresses a different set of genes [2].”
BackgroundHájková, H., Fritz, M. H.-Y., Haškovec, C., Schwarz, J., Šálek, C., Marková, J., Krejčík, Z., Merkerová, M. D., Kostečka, A., Vostrý, M., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0066-4 · Cited by 13
“inv(16), specific hypomethylation that may play a role in upregulation of some previously described inv(16) overexpressed genes [8].”
BackgroundResultInfluentialmiRNA-650 exerts anti-leukemia activity by inhibiting cell proliferation through Gfi1 targeting
Yuan, C., Xu, L., Du, P., & Pang, J. (2018) · Tumori Journal · doi:10.5301/tj.5000643 · Cited by 12
“In contrast, elevated expression of Gfi1 has been reported in patients with chronic myeloid leukemia, and wide variations in Gfi1 expression have been detected in different AML subtypes (15, 16).”
BackgroundHernandez-Valladares, M., Vaudel, M., Selheim, F., Berven, F. S., & Bruserud, Ø. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1352474 · Cited by 12
Farries, G., Gough, K., Parnell, A., McGivney, B., McGivney, C. L., McGettigan, P., Machugh, D., Katz, L., & Hill, E. (2019) · Animal Genetics · doi:10.1111/age.12848 · Cited by 10
“MN1 has mostly been investigated in terms of its role in the pathogenesis of leukaemia in humans (Valk et al. 2004; Heuser et al. 2006; Carella et al. 2007).”
BackgroundBrown, M. A., Edwards, M. A., Alshiraihi, I., Geng, H., Dekker, J. D., & Tucker, H. O. (2020) · Genes and Immunity · doi:10.1038/s41435-020-0094-8 · Cited by 12
Singh, S., Sarkar, T., Jakubison, B. L., Gadomski, S. J., Spradlin, A., Gudmundsson, K. O., & Keller, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934624 · Cited by 14
“Furthermore, analysis of ID gene expression in an AML patient cohort showed that high levels of ID gene expression were correlated with FLT3-ITD, RAS, EVI-1 and C/EBPA mutations, suggesting ID gene expression may be induced downstream of oncogene activated signal transduction pathways (111).”
BackgroundGene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia
Mills, K. (2008) · Frontiers in bioscience · doi:10.2741/3026 · Cited by 14
FCHSD2 predicts response to chemotherapy in acute myeloid leukemia patients
Han, Y., Cui, J., Lu, Y., Sue, S., Arpaia, E., Mak, T. W., & Minden, M. D. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.06.011 · Cited by 12
Phenotype Data: A Neglected Resource in Biomedical Research?
Groth, P., & Weiss, B. (2006) · Current Bioinformatics · doi:10.2174/157489306777828008 · Cited by 12
“[46] found molecular signatures from gene expression profiles of acute myeloid leukemia (AML) patients, by clearly discriminating 16 patient groups within AML.”
BackgroundAref, S., Ibrahim, L., Morkes, H., Azmy, E., & Ebrahim, M. (2013) · Hematology · doi:10.1179/1607845412y.0000000065 · Cited by 12
Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics
Wang, T., & Chao, A. (2007) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(08)60024-8 · Cited by 13
“For instance, we have gained insight into the host response to SARS infection [3], tumor biology of MICROARRAY ANALYSIS OF GENE EXPRESSION OF CANCER TO GUIDE THE USE OF CHEMOTHERAPEUTICS Tzu-Hao Wang1,2*, Angel Chao1 1Department of Obstetrics and Gynecology, Lin-Kou Medical Center, Chang Gung Memorial Hospital, Chang…”
BackgroundMethodInfluentialDefining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
Galera, P. K., Dilip, D., Derkach, A., Chan, A. C. L., Zhang, Y., Persaud, S., Mishra, T., Kramer, K., Kathpalia, M., Liu, Y., et al. (2025) · Blood · doi:10.1182/blood.2024026273 · Cited by 14
Highly robust model of transcription regulator activity predicts breast cancer overall survival
Dong, C., Liu, J., Chen, S., Dong, T., Jiang, G., Wang, Y., Wu, H., Reiter, J. L., & Liu, Y. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0688-z · Cited by 15
“A transcriptional regulator activity based risk score formula was constructed by including statistically significant genes weighted by their estimated multivariable Cox’s regression adapted coefficients [22].”
MethodRosenberg, M. W., Watanabe‐Smith, K., Tyner, J. W., Tognon, C. E., Druker, B. J., & Borate, U. (2020) · Oncotarget · doi:10.18632/oncotarget.27656 · Cited by 11
Expressions of CD274 (PD-L1) and CD47 rReceptors on the sSurface of bBlast cCells in AML pPatients
Hamad, H. M., Shabeeb, Z. A., & Awad, M. M. (2022) · Iraqi Journal of Science · doi:10.24996/ijs.2022.63.6.6 · Cited by 11
“A previous research of a group of 285 AML patients with different cytogenetic and molecular deficiencies [56] confirmed this hypothesis, showing a significantly higher risk of death in the elevated CD47 expression patients when patients were dichotomized into higher and lower CD47 expression groups.”
MethodArsenic trioxide induces apoptosis in the THP1 cell line by downregulating EVI-1
ZHOU, L.-Y., CHEN, F.-Y., Shen, L., Wan, H., & ZHONG, J.-H. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1716 · Cited by 12
“Apoptosis plays a key role in multicellular organisms by maintaining normal development and homeostasis, and allowing organisms to respond appropriately to environmental stimuli (6).”
Jen, C.-H., Yang, T.-P., Tung, C.-Y., Su, S., Lin, C.-H., Hsu, M., & Wang, H. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-58 · Cited by 11
“These identified genes form an expression signature that can be used to assist clinical management decisions such as clinical trail risk assessment, treatment selection, or cancer prognosis [1-5].”
BackgroundAllogeneic stem cell transplantation in first complete remission
Oran, B., & Weisdorf, D. J. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834ba94c · Cited by 11
Yang, J., & Schiffer, C. A. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.32 · Cited by 11
An efficient method to estimate the optimum regularization parameter in RLDA
Bakir, D., James, A. P., & Zollanvari, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw506 · Cited by 11
“, 2002); (e) and (l) (Valk et al., 2004); (f) and (m) (van de Vijver et al.”
BackgroundInfluentialRAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
Zebisch, A., Caraffini, V., & Sill, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225756 · Cited by 11
IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells
van Gils, N., Verhagen, H. J. M. P., Rutten, A. P., de Menezes, R. X., Tsui, M.-L., Vermue, E., Dekens, E., Brocco, F., Denkers, F., Kessler, F. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002812 · Cited by 11
Lysosome-mediated chemoresistance in acute myeloid leukemia
Cuesta‐Casanovas, L., Delgado-Martínez, J., Cornet-Masana, J. M., Carbo, J. M. C. I., Clément-Demange, L., & Risueño, R. M. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.122 · Cited by 15
Rocha, S. M., Socorro, S., Passarinha, L. A., & Maia, C. J. (2022) · Data · doi:10.3390/data7050064 · Cited by 14
“[138] reported a significant underexpression.”
Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?
Chigaev, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00134 · Cited by 13
“Epigenetic regulation of ATP1B2 expression was also reported in malignant gliomas (van den et al., 2006).”
BackgroundSerrano, E., Carnicer, M. J., Lasa, A., Orantes, V., Peña, J., Brunet, S., Aventin, A. M., Sierra, J., & Nomdedeu, J. F. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.11.038 · Cited by 11
Ferrer‐Alcón, M., Arteta, D., Guerrero, M. ª. J., Fernández‐Orth, D., Simón, L., & Martínez, A. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.10.014 · Cited by 12
“…is by far the field with the most data generated by transcriptional studies (Eszlinger et al., 2007; Wang et al., 2007; van de Vijver et al., 2002; Valk et al., 2004; Alizadeh et al., 2000; Dyrskjot et al., 2004; Alon et al., 1999; Luo et al., 2001), many other fields have begun to follow their…”
Su, G., Lian, X., Tan, D., Tao, H., Liu, H., Chen, S., Yin, H., Wu, D., & Yin, B. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.924118 · Cited by 11
Genomics in Multiple Myeloma: Biology and Clinical Implications
Chng, W. J., & Fonseca, R. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.6.563 · Cited by 11
“These unique subtypes have recently been validated by gene expression profiling studies, where subgroups identified by unsupervised clustering essentially correspond to the genetic subtypes [7–10].”
BackgroundAqaqe, N., Yassin, M., Yassin, A. A., Ershaid, N., Katz-Even, C., Zipin‐Roitman, A., Kugler, E., Lechman, E. R., Gan, O. I., Mitchell, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3215 · Cited by 13
Damm, F., Wagner, K., Görlich, K., Morgan, M. A., Thol, F. R., Yun, H., Delwel, R., Valk, P. J. M., Löwenberg, B., Heuser, M., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09144.x · Cited by 11
“These results were confirmed in an independent cohort of 293 AML patients, provided by Valk et al (2004).”
MethodResultSelf-citationGrowth and Differentiation Effects of Homer3 on a Leukemia Cell Line
Li, Z., Qiu, H.-Y., Jiao, Y., Cen, J., Fu, C., Hu, S., Zhu, M.-Q., Wu, D., & Qi, X. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2525 · Cited by 13
“And decreased expression for Homer3 was associated with a poor outcome in AML (Valk et al., 2004).”
BackgroundLeecharendkeat, A., Tocharoentanaphol, C., & Auewarakul, C. U. (2008) · International Journal of Cancer · doi:10.1002/ijc.23796 · Cited by 11
“2) The Netherlands Valk et al.(25) 17/285 (6) Asia Taiwan Lin et al.”
BackgroundStratification of Acute Myeloid Leukemia Based on Gene Expression Profiles
Mano, H. (2004) · International Journal of Hematology · doi:10.1532/ijh97.04111 · Cited by 11
“Similarly, Valk et al measured the expression levels of approximately 13,000 genes in BM MNCs isolated from 285 patients with AML [ 30 ].”
BackgroundHeterogeneity of gene expression profiles in head and neck cancer
Pramana, J., Pimentel, N., Hofland, I., Wessels, L. F. A., van Velthuysen, M. F., Atsma, D., Rasch, C. R. N., van den Brekel, M. W. M., & Begg, A. C. (2007) · Head & Neck · doi:10.1002/hed.20621 · Cited by 11
Mei, L., Jaitly, V., Wang, I., Hu, Z., Chen, L., Wahed, M. A., Kanaan, Z., Rios, A., & Nguyen, A. N. D. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1810.13247 · Cited by 12
Cao, J., Huang, S., & Li, X. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.07.298 · Cited by 10
Xu, X., Sun, R., Li, Y., Wang, J., Zhang, M., Xiong, X., Xie, D., Jin, X., & Zhao, M. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01550-7 · Cited by 11
Molecular profiling in the age of cancer genomics
Lin, J., & Li, M. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.3.263 · Cited by 12
Reboiro‐Jato, M., Glez‐Peña, D., Díaz, F., & Fdez‐Riverola, F. (2012) · International Journal of Data Mining and Bioinformatics · doi:10.1504/ijdmb.2012.050267 · Cited by 10
“These data sets were taken from the previous studies of Gutiérrez et al. (2005), Bullinger et al. (2004) and Valk et al. (2004).”
MethodAbidin, F. N. Z., & Westhead, D. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1270 · Cited by 12
“33, 72) are regulated by FKH1 and FKH2.”
BackgroundCellular Processes Involved in Jurkat Cells Exposed to Nanosecond Pulsed Electric Field
Li, H., Liu, S., Yang, X., Du, Y., Luo, J., Tan, J., & Sun, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235847 · Cited by 10
“In addition, there is no significant difference in the expression of several genes in tumor tissues and normal tissues, including DHX16, FUS, DHX15, NAA38, and SKIV2L2 [12].”
BackgroundHigh expression of HOXA5 is associated with poor prognosis in acute myeloid leukemia
Yang, Y. B., Zhong, F., Huang, X., Zhang, N., Du, J., Long, Z., Zheng, B., Lin, W., Liu, W., & Ma, W. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100673 · Cited by 10
Identification and validation of CALCRL-associated prognostic genes in acute myeloid leukemia
Huang, Z., Zhang, H., Xing, C., Zhang, L., Zhu, H., Deng, Z., Yin, L., Dong, E., Wang, C., & Peng, H. (2021) · Gene · doi:10.1016/j.gene.2021.146009 · Cited by 10
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.